VANCOUVER, British Columbia, Aug. 26, 2019 (GLOBE NEWSWIRE)
-- NewLeaf
Brands Inc. (CSE:NLB) (OTC: NLBIF)
(FSE:0NF) (“NewLeaf Brands” or the “Company”) is pleased to
announce that the Company has been working to develop a
proprietary line of fully water soluble, CBD and probiotic
mixtures. The company has been working with world renowned
PHD scientist and seven time Nobel Peace Prize nominee to
develop this line of proprietary CBD and probiotic powder
formulations. The powder formulas will come in the following
three flavored mixtures: blood orange morning mixture
infused with a healthy dose of caffeine, exotic berry
mid-day mixture containing a proprietary vitamin blast and
passion fruit night time mixture containing melatonin. The
Company has developed a number of in house product offerings
utilizing the proprietary formula. In addition, the company
plans to license the formula to product companies worldwide.
You can view some of the product offerings at www.freshwavecbd.com.
CEO of NewLeaf Brands, Josh Bartch, commented “We are
incredibly excited to debut our new line of products in the
near future. We have been working hard with our science team
to develop a truly cutting edge, healthy, versatile and
great tasting product. In the market place today it’s
incredibly important to make something truly exceptional and
unique that sets you apart from the rest of the field, and
with Fresh Wave we have accomplished that."
ABOUT NewLeaf Brands
NewLeaf Brands, Inc. is
an innovative Cannabidiol (“CBD”) lifestyle Company. Through
the Company’s wholly-owned subsidiaries We are Kured, LLC,
Drink Fresh Water, LLC, ReLyfe Brand, LLC and TeaLief Brand,
LLC the Company’s main business activities encompass the
development, marketing, and distribution of CBD products
(including vaporizer pens/cartridges, hot/cold tea, softgel
capsules and beverages) throughout North America, South
America, and Europe. In addition, NewLeaf Brands, Inc. has
extensive retail and cultivation land investments in Oregon,
USA.
More News and Media
-
DISCLAIMER - Writer has not been paid for this
article nor holds a position in its shares